Use of novel proteosome inhibitors as a therapeutic strategy in lymphomas current experience and emerging concepts

SUNScholar Research Repository

Show simple item record

dc.contributor.author Abayomi E.A.
dc.contributor.author Sissolak G.
dc.contributor.author Jacobs P.
dc.date.accessioned 2011-05-15T16:18:16Z
dc.date.available 2011-05-15T16:18:16Z
dc.date.issued 2007
dc.identifier.citation Transfusion and Apheresis Science
dc.identifier.citation 37
dc.identifier.citation 1
dc.identifier.issn 14730502
dc.identifier.other 10.1016/j.transci.2007.04.009
dc.identifier.uri http://hdl.handle.net/10019.1/14580
dc.description.abstract Precedent from preclinical experiments coupled with two pivotal phase 2 studies in myeloma has focused attention on a potential role for ubiquitin-proteasome pathway in modulating a number of events that occur commonly in the neoplastic process involving proteins in the regulation of cells cycling, growth and differentiation. This influence is vested in the proteasomes which are large complexes of proteolytic enzymes responsible for degradation of many of these intracellular messengers. Logically interest has centred on molecules having the capacity to influence, by degradation, such molecules and although a number of agents are in development bortezomib is the only one currently in clinical use. Velcade, formerly PS-341, is a novel dipeptide boronic acid capable of reversibly inhibiting the 26S proteasome through a range of activities. The latter are anti-proliferative and proapoptotic with the latter blocking nuclear transcription via NF-κ B in addition to down regulating adhesion and inhibiting angiogenesis. Additional changes are mediated in protein folding within the endoplasmic reticulum and contribute to cell death. These concepts are given focus by considering their introduction into treatment of lymphoreticular malignancy. © 2007.
dc.subject bortezomib
dc.subject dexamethasone
dc.subject DNA
dc.subject I kappa B
dc.subject immunoglobulin enhancer binding protein
dc.subject proteasome inhibitor
dc.subject protein p53
dc.subject rituximab
dc.subject vascular cell adhesion molecule 1
dc.subject vasculotropin
dc.subject article
dc.subject B cell lymphoma
dc.subject bacterial pneumonia
dc.subject candidiasis
dc.subject carcinogenesis
dc.subject cell cycle
dc.subject cell death
dc.subject cell differentiation
dc.subject cell growth
dc.subject endoplasmic reticulum
dc.subject fatigue
dc.subject herpes zoster
dc.subject human
dc.subject hyponatremia
dc.subject large cell lymphoma
dc.subject lymphoma
dc.subject multiple myeloma
dc.subject natural killer cell
dc.subject nonhodgkin lymphoma
dc.subject peripheral neuropathy
dc.subject positron emission tomography
dc.subject T lymphocyte
dc.subject thrombocytopenia
dc.subject vasculitis
dc.subject Active Transport, Cell Nucleus
dc.subject Apoptosis
dc.subject Boronic Acids
dc.subject Cell Adhesion
dc.subject Cell Cycle
dc.subject Cell Differentiation
dc.subject Clinical Trials, Phase II as Topic
dc.subject Endoplasmic Reticulum
dc.subject Humans
dc.subject Lymphoma
dc.subject Neoplasm Proteins
dc.subject Neovascularization, Pathologic
dc.subject NF-kappa B
dc.subject Protease Inhibitors
dc.subject Proteasome Endopeptidase Complex
dc.subject Pyrazines
dc.subject Ubiquitin
dc.title Use of novel proteosome inhibitors as a therapeutic strategy in lymphomas current experience and emerging concepts
dc.type Article
dc.description.version Article


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record